News: AbbVie and MPP complete licensing agreement to ensure access to G/P in 99 low and middle-income countries

At an American Association for the Study of Liver Diseases (AASLD) meeting last month, pharmaceuticals company AbbVie and the Medicines Patent Pool (MPP) announced a new, royalty-free licensing agreement for glecaprevir/pibrentasvir (G/P), a World Health Organization-recommended treatment for individuals suffering from chronic hepatitis C.

According to the AbbVie press release, under the license, WHO-prequalified manufacturers in 99 low- and middle-income countries (LMIC) and territories will be able to license, produce and sell generic medicines containing G/P at affordable prices.

Read the full press release from AbbVie here.

Read the full press release from MPP here.

Access the license agreement here.

Image “Pharmacy in Marrakech” by John Althouse Cohen is licensed under CC BY-ND 2.0.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s